Glaukos Corp (NYSE:GKOS) CFO Joseph E. Gilliam sold 3,647 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $68.50, for a total value of $249,819.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Joseph E. Gilliam also recently made the following trade(s):

  • On Monday, May 13th, Joseph E. Gilliam sold 2,603 shares of Glaukos stock. The stock was sold at an average price of $65.14, for a total value of $169,559.42.
  • On Tuesday, February 19th, Joseph E. Gilliam sold 5,000 shares of Glaukos stock. The stock was sold at an average price of $70.03, for a total value of $350,150.00.

NYSE GKOS opened at $67.23 on Friday. The company has a current ratio of 6.72, a quick ratio of 5.38 and a debt-to-equity ratio of 0.07. Glaukos Corp has a fifty-two week low of $34.00 and a fifty-two week high of $83.14.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.08. The firm had revenue of $54.03 million for the quarter, compared to the consensus estimate of $50.13 million. Glaukos had a negative return on equity of 6.90% and a negative net margin of 5.93%. As a group, equities research analysts expect that Glaukos Corp will post -0.3 earnings per share for the current fiscal year.

Several analysts have recently issued reports on GKOS shares. Wells Fargo & Co reaffirmed a “buy” rating on shares of Glaukos in a report on Wednesday, March 20th. Stifel Nicolaus upped their price objective on Glaukos from $58.00 to $68.00 and gave the stock a “positive” rating in a report on Thursday, February 28th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $80.00 price objective on shares of Glaukos in a report on Thursday, February 28th. BTIG Research started coverage on Glaukos in a report on Friday, March 8th. They set a “neutral” rating and a $66.02 price objective on the stock. Finally, Zacks Investment Research raised Glaukos from a “sell” rating to a “hold” rating and set a $74.00 price objective on the stock in a report on Monday, March 4th. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $72.56.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Glaukos by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,805,222 shares of the medical instruments supplier’s stock valued at $182,059,000 after purchasing an additional 90,235 shares during the last quarter. BlackRock Inc. increased its position in shares of Glaukos by 6.3% during the 4th quarter. BlackRock Inc. now owns 2,563,895 shares of the medical instruments supplier’s stock valued at $144,014,000 after purchasing an additional 151,304 shares during the last quarter. William Blair Investment Management LLC increased its position in shares of Glaukos by 0.4% during the 1st quarter. William Blair Investment Management LLC now owns 2,465,432 shares of the medical instruments supplier’s stock valued at $193,216,000 after purchasing an additional 9,401 shares during the last quarter. FMR LLC increased its position in shares of Glaukos by 85.8% during the 4th quarter. FMR LLC now owns 2,280,178 shares of the medical instruments supplier’s stock valued at $128,077,000 after purchasing an additional 1,052,748 shares during the last quarter. Finally, Lord Abbett & CO. LLC increased its position in shares of Glaukos by 12.8% during the 4th quarter. Lord Abbett & CO. LLC now owns 2,106,080 shares of the medical instruments supplier’s stock valued at $118,298,000 after purchasing an additional 238,254 shares during the last quarter. 98.83% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.dailypolitical.com/2019/05/19/glaukos-corp-gkos-cfo-joseph-e-gilliam-sells-3647-shares.html.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.

Featured Story: Quiet Period Expirations

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.